Geron Reports 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Press/Media

Period4 Jan 2024

Media coverage

1

Media coverage

  • TitleGeron Reports 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
    Media name/outletManufacturing Close-Up
    Country/TerritoryUnited States
    Date4/01/24
    PersonsJohn Mascarenhas
View all 1
View less